

Abstract

The invention relates to combinations of an aminosugar and a beta-2-adrenoceptor agonist, such as salbutamol, for the treatment of diseases associated with hypersensitivity and inflammation, in particular hypersensitivity skin diseases. The aminosugar is preferably a monosaccharide derivative.